Fig. 2: METTL3 promoted breast cancer cell proliferation.
From: Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway
A M6A level was higher in breast cancer tissues (tumor) than adjacent normal tissues (normal) (n = 32). B The mRNA expression of METTL3 was higher in breast cancer tissues (tumor) than adjacent normal tissues (normal) (n = 90), ***p < 0.001. The relative RNA level was calculated by the 2−ΔΔCt method and normalized based on β-actin. The average mRNA level of adjacent normal tissues was set as 1. C Kaplan–Meier survival curves of disease-free survival (DFS) in 90 breast cancer patients based on METTL3 expression showed that higher expression of METTL3 tended to be correlated with shorter DFS of breast cancer patients. The log-rank test was used to compare the difference between the two groups (p = 0.062). D–F Knockdown of METTL3 significantly decreased the growth of SUM-1315, MCF-7, and BT-474 cells by CCK-8 assay. *p < 0.05, **p < 0.01, ***p < 0.01 vs. scrambled control group (shNC). G, H Knockdown of METTL3 decreased the colony formation efficiency in SUM-1315 and MCF-7 cells. ***p < 0.001 vs. scrambled control group (shNC). I, J Cell cycle analyzed by flow cytometry. Histogram showed that METTL3 knockdown arrested at the G1 phase in SUM-1315 and MCF-7 cells. *p < 0.05, **p < 0.01 vs. scrambled control group (shNC). Data represented the mean ± SD.
